Iron Triangle Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Iron Triangle Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-555,140	Closed	-$45.7M	–	30
2024 Q2	$45.7M	Buy	+555,140	New	+$46.2M	4.65%	12
2024 Q1	–	Sell	-200,000	Closed	-$19.3M	–	30
2023 Q4	$19.3M	Buy	+200,000	New	+$17.7M	2.5%	19

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Iron Triangle Partners's BMRN Position: Q3 2024 in Review

Iron Triangle Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 555,140 shares — an estimated $45.7M sold.

Iron Triangle Partners first reported a position in BMRN in Q4 2023 and held it in 2 quarters. The position peaked at $45.7M in Q2 2024. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

Iron Triangle Partners reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Iron Triangle Partners sold 555,140 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $45.7M.
Iron Triangle Partners first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 2 quarters.
Iron Triangle Partners's BioMarin Pharmaceuticals position peaked at $45.7M in Q2 2024.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Iron Triangle Partners's 13F filing for Q3 2024, filed 14 Nov 2024.